Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12761250 | 0.86 | GP6 (0.37) | ENPP2IDO1 | |
| SCHEMBL4655029 | 0.79 | GP6 (0.49) | — | |
| SCHEMBL27289681 | 0.79 | ENPP2 (0.30) | ENPP2IDO1 | |
| SCHEMBL704854 | 0.78 | MGAM (0.43) | IDO1 | |
| SCHEMBL13113241 | 0.78 | ENPP2 (0.32) | ENPP2IDO1 | |
| SCHEMBL4644949 | 0.78 | IDO1 (0.42) | ENPP2IDO1 | |
| SCHEMBL513232 | 0.78 | ALDH1A1 (0.44) | IDO1 | |
| SCHEMBL1109610 | 0.78 | ENPP2 (0.32) | ENPP2IDO1 | |
| SCHEMBL702625 | 0.78 | DCUN1D1 (0.50) | IDO1 | |
| SCHEMBL859970 | 0.78 | HSD17B1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569847-B1 | Inhibitors of cathepsins for treating muscular dystrophy, osteoporosis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergy, or Chagas disease | NAEJA PHARMACEUTICALS INC. (CA) | 2003-05-27 | — | — | US | claimed |
| JP-2002544121-A | — | — | 2002-12-24 | — | — | JP | claimed |
| EP-1165506-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059881-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2000-10-12 | — | — | WO | claimed |
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| US-6569847-B1 | Inhibitors of cathepsins for treating muscular dystrophy, osteoporosis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergy, or Chagas disease | NAEJA PHARMACEUTICALS INC. (CA) | 2003-05-27 | — | — | US | disclosed |
| EP-1165506-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059881-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | ENPP2 3278/4885IDO1 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.